Search results for "Staging."

showing 10 items of 715 documents

The Value of Sonography and Lymphography in the Detection of Retroperitoneal Metastases in Testicular Tumors

1979

Lymphography has led to falsely negative or falsely positive diagnoses in 10 to 45 per cent of the cases of testicular tumor metastases reported in the literature. In our comparative study of lymphography and sonography in the preoperative staging of 29 malignant testicular tumors lymphography was accurate in 58.5 per cent of the cases, while sonography had an accuracy rate of 82.5 per cent. Sonography was superior to lymphography in the evaluation of hilar lymph node metastases and their extent, as well as for routine checkups after lymphadenectomy or irradiation.

AdultMalemedicine.medical_specialtybusiness.industryUrologymedicine.medical_treatmentLymphographyTesticular tumorDysgerminomaSurgerymedicine.anatomical_structurePreoperative stagingTesticular NeoplasmsLymphatic MetastasismedicineHumansLymph Node ExcisionLymphadenectomyRetroperitoneal NeoplasmsRadiologybusinessLymph nodeUltrasonographyJournal of Urology
researchProduct

Surgical treatment of gastric cancer in Latvia: Results of centralized experience

2009

Although the mortality for gastric cancer is decreasing in Western Europe and United States, it still remains high in Eastern Europe. This study was aimed at evaluating short- and long-term results of surgical treatment of gastric cancer performed in Latvia Oncology Center.Retrospectively collected data from 461 patients who underwent gastrectomy with curative intent in Latvia Oncology Center from January 2001 to December 2005 were analyzed statistically.An average (range) of 92.2 (81-102) R0-R1 gastrectomies was performed each year. Post-operative complications occurred in 75 patients (16.3%); in-hospital mortality was 3.3%. The overall 5-year survival was 50.8%. In 444 cases (96.3%) there…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentOutcome and Process AssessmentResectionPostoperative ComplicationsGastrectomyStomach Neoplasms80 and overmedicineHumansHospital MortalityRegistriesSurgical treatmentAgedNeoplasm StagingRetrospective StudiesAged 80 and overCurative intentAnalysis of VarianceSurgical treatmentChi-Square DistributionGastric cancer; Surgical treatment; Prognosisbusiness.industryCancerGeneral MedicineMiddle AgedPrognosismedicine.diseaseLatviaSurgeryHealth CareSurvival RateOutcome and Process Assessment Health CareOncologyWestern europeFemaleSurgeryGastrectomyGastric cancerbusinessEuropean Journal of Surgical Oncology (EJSO)
researchProduct

Peri-Tumoral Inflammatory Cell Infiltration in OSCC: A Reliable Marker of Local Recurrence and Prognosis? An Investigation Using Artificial Neural Ne…

2011

The presence of inflammatory reaction in peri-tumoural connective tissue is generally considered as a defense mechanism against cancer, but inflammation tissue in malignant transformation and early steps of oncogenesis has been recently proven to play a supporting and aggravating role in some carcinomas. Aims of this retrospective study were to evaluate in OSCCs the independent association of peri-tumoral inflammatory infiltrate (PTI) with local recurrence (LR) or survival outcome, and to verify whether PTI can be considered a marker of prognosis. Data from 211 cases of OSCC, only surgically treated between 1990 and 2000, were collected and retrospectively analyzed for PTI and the event LR…

AdultMalesurvival ratemedicine.medical_specialtyPathologyoral carcinoma recurrence survival rate markerrecurrenceImmunologyKaplan-Meier EstimateLogistic regressionLower riskGastroenterologyoral carcinomaMalignant transformationSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineCarcinomaHumansImmunology and AllergyStage (cooking)Survival rateAgedNeoplasm StagingAged 80 and overInflammationmarkerPharmacologyUnivariate analysisbusiness.industrymarker; oral carcinoma; recurrence; survival rate;CancerMiddle AgedPrognosismedicine.diseaseTumor BurdenCarcinoma Squamous CellFemaleMouth NeoplasmsNeural Networks ComputerNeoplasm GradingbusinessInternational Journal of Immunopathology and Pharmacology
researchProduct

Transforming Growth Factor Beta 1 Serum Levels in Patients with Preinvasive and Invasive Lesions of the Breast

2004

Transforming growth factor beta (TGF-beta)1 is thought to be involved in breast carcinogenesis. TGF-beta1 acts in an antiproliferative manner in the early stages of breast carcinogenesis, but promotes tumor progression and metastases in the advanced stages of the disease. No data have been published on serum TGF-beta1 in breast cancer. We investigated TGF-beta1 serum levels in patients with breast cancer (n=135), ductal carcinoma in situ (DCIS) I to III (n=67) or fibroadenoma (n=35), and in healthy women (n=40) to determine its value as a differentiation marker between malignant, pre-invasive and benign diseases and as a predictive marker for metastatic spread. Median (range) TGF-beta1 seru…

AdultOncology0301 basic medicinemedicine.medical_specialtyPathologyCancer ResearchMammary glandClinical BiochemistryCA 15-3Breast NeoplasmsPathology and Forensic MedicineTransforming Growth Factor beta103 medical and health sciencesBreast cancer0302 clinical medicineTransforming Growth Factor betaInternal medicinemedicineHumansNeoplasm Invasivenessskin and connective tissue diseasesEstrogen Receptor StatusAgedNeoplasm StagingAged 80 and overPredictive markerbusiness.industryMiddle AgedDuctal carcinomamedicine.diseaseFibroadenomamedicine.anatomical_structure030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisbusinessThe International Journal of Biological Markers
researchProduct

Validation of tumour-free distance as novel prognostic marker in early-stage cervical cancer: a retrospective, single-centre, cohort study

2021

Background: The aim of the present study was to assess the prognostic value of tumour-free distance (TFD), defined as the minimum distance of uninvolved stroma between the tumour and peri-cervical stromal ring, in early-stage cervical cancer. Methods: Patients with pathologic FIGO 2009 stage IA1–IIA2 cervical cancer, treated by primary radical surgical treatment between 01/2000 and 11/2019, were retrospectively included. Adjuvant treatment was administered according to the presence of previously established pathologic risk factors. TFD was measured histologically on the hysterectomy specimen. Pre-operative TFD measured at MRI-scan from a cohort of patients was reviewed and compared with pat…

AdultOncologyCancer Researchmedicine.medical_specialtyMultivariate analysismedicine.medical_treatmentUterine Cervical NeoplasmsHysterectomyArticlesurgery03 medical and health sciences0302 clinical medicineSurgical oncologyInternal medicinelocally advanced cervical cancerHumansMedicineStage (cooking)AgedNeoplasm StagingRetrospective StudiesAged 80 and overCervical cancer...Hysterectomybusiness.industrylocally advanced cervical cancer surgeryMiddle AgedPrognosismedicine.diseaseMagnetic Resonance ImagingSurvival AnalysisSettore MED/40 - GINECOLOGIA E OSTETRICIATreatment OutcomeOncologyLymphatic Metastasis Magnetic Resonance ImagingLymphatic Metastasis030220 oncology & carcinogenesisCohortRadiographic Image Interpretation Computer-AssistedFemaleLymphbusinessCohort studyBritish Journal of Cancer
researchProduct

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positiv…

2015

Purpose Capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 is an adjuvant trial to investigate the integration of capecitabine into a regimen of epirubicin and docetaxel for node-positive early BC. Patients and Methods Patients with operable node-positive BC (T1-3/N1-3) were eligible. After surgery, 1,384 patients were randomly assigned to receive epirubicin plus cyclophosphamide (EC; 90 and 600 mg/m2, respectively, × four cycles), followed by docetaxel (100 mg/m2 × four cycles; EC-T) or epirubicin plus docetaxel (ET; 90 and 75 mg/m2, respectively, × four cycles), followed by capecitabine (1,250 mg/m2 twice a day on days 1 to 14, × four cycles; ET-X); all regime…

AdultOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBreast NeoplasmsDocetaxelDisease-Free SurvivalDrug Administration ScheduleCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOdds RatiomedicineAdjuvant therapyHumansCyclophosphamideCapecitabineAgedEpirubicinNeoplasm StagingChemotherapybusiness.industryMiddle Agedmedicine.diseaseMetastatic breast cancerSurgeryRegimenTreatment OutcomeOncologyDocetaxelChemotherapy AdjuvantFluorouracilLymphatic MetastasisFemaleTaxoidsFluorouracilLymph NodesbusinessFollow-Up Studiesmedicine.drugEpirubicinJournal of Clinical Oncology
researchProduct

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial

2021

Introduction: Large and consistent evidence supports the use of eribulin mesylate in clinical practice in third or later line treatment of metastatic triple negative breast cancer (mTNBC). Conversely, there is paucity of data on eribulin efficacy in second line treatment. Methods: We investigated outcomes of 44 mTNBC patients treated from 2013 through 2019 with second line eribulin mesylate in a multicentre retrospective study involving 14 Italian oncologic centres. Results: Median age was 51 years, with 11.4% of these patients being metastatic at diagnosis. Median overall survival (OS) and progression free survival (PFS) from eribulin starting were 11.9 (95%CI: 8.4-15.5) and 3.5 months (95…

AdultOncologyEribulin Mesylatemedicine.medical_specialtyeribulin mesylatemedicine.medical_treatmentTriple Negative Breast Neoplasmschemotherapytriple negative metastatic breast cancer03 medical and health scienceschemistry.chemical_compound0302 clinical medicineadjuvantInternal medicineAntineoplastic Combined Chemotherapy Protocols80 and overmedicineHumansChemotherapy; Efficacy outcomes; Eribulin mesylate; Toxicity outcomes; Triple negative metastatic breast cancerProgression-free survivalFuransAdverse effectTriple-negative breast cancerAgedNeoplasm StagingRetrospective StudiesAged 80 and overChemotherapybusiness.industryRetrospective cohort studyGeneral MedicineKetonesMiddle Agedmedicine.diseaseMetastatic breast cancerNeoadjuvant TherapyProgression-Free SurvivalchemistryChemotherapy AdjuvantFemale030211 gastroenterology & hepatologytoxicity outcomesefficacy outcomeschemotherapy; efficacy outcomes; eribulin mesylate; toxicity outcomes; triple negative metastatic breast cancer; adult; aged; aged; 80 and over; antineoplastic combined chemotherapy protocols; chemotherapy; adjuvant; female; furans; humans; ketones; middle aged; neoadjuvant therapy; neoplasm staging; progression-free survival; retrospective studies; triple negative breast neoplasmsbusinessResearch PaperEribulinInternational Journal of Medical Sciences
researchProduct

Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer

2009

Background: This phase 2 trial was designed to evaluate the efficacy and toxicity of a combination of docetaxel, gemcitabine, and oxaliplatin for platinum- and paclitaxel-pretreated epithelial ovarian cancer. Patients and Methods: Heavily pretreated patients (N = 30; median age, 61 years) received docetaxel, 55 mg/m2; gemcitabine, 500 mg/m2 (day 1); and oxaliplatin, 70 mg/m2 (day 2) biweekly. Twelve patients had platinum-sensitive disease, and 18 patients had platinum-resistant disease. Results: Median follow-up was 18.6 months. No differences in patient characteristics were observed between patients with carboplatinum-sensitive and carboplatinum-resistant disease. In patients with carbopla…

AdultOncologymedicine.medical_specialtyAdolescentOrganoplatinum CompoundsPaclitaxelAnemiaDocetaxelNeutropeniaDeoxycytidineYoung Adultchemistry.chemical_compoundRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineFallopian Tube NeoplasmsHumansNeoplasm InvasivenessProspective StudiesPeritoneal NeoplasmsAgedNeoplasm StagingOvarian Neoplasmsbusiness.industryObstetrics and GynecologyCombination chemotherapyMiddle AgedPrognosismedicine.diseaseGemcitabineGemcitabineOxaliplatinOxaliplatinTreatment OutcomeOncologyDocetaxelPaclitaxelchemistryFemaleTaxoidsOvarian cancerbusinessmedicine.drugInternational Journal of Gynecological Cancer
researchProduct

Multivariate independent prognostic factors in endometrial carcinoma: A clinicopathologic study in 181 patients: 10 years experience at the Departmen…

2003

The aim of this study was to evaluate the biologic outcome of endometrial carcinomas as compared to clinical and pathologic parameters and to identify multivariate independent prognostic factors. Charts were abstracted from patients with endometrial carcinoma from 1985 to 1995. Data on clinicopathologic variables, adjuvant treatment, site of recurrence, and survival were collected. chi2 test was used to test association between variables. Kaplan-Maier method was used for survival analysis and Cox proportional hazards model for multiple regression analysis. Univariate analysis revealed that FIGO stage, tumor grade, depth of myometrial invasion, biochemical analysis of progesterone receptor s…

AdultOncologymedicine.medical_specialtyMultivariate analysisAdenocarcinomaMedical RecordsCarcinoma AdenosquamousObstetrics and gynaecologyGermanyInternal medicineDiabetes MellitusCarcinomaHumansMedicineNeoplasm InvasivenessStage (cooking)Survival analysisAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overMetaplasiaUnivariate analysisbusiness.industryProportional hazards modelObstetrics and GynecologyMiddle AgedProgesterone Receptor StatusPrognosismedicine.diseaseSurvival AnalysisEndometrial NeoplasmsOncologyLymphatic MetastasisMultivariate AnalysisFemaleNeoplasm Recurrence LocalbusinessInternational Journal of Gynecological Cancer
researchProduct

Influence of Intraperitoneal Dissemination Assessed by Laparoscopy on Prognosis of Advanced Ovarian Cancer: An Exploratory Analysis of a Single-Insti…

2014

Purpose: The aim of this study was to investigate whether preoperative laparoscopic evaluation of the dissemination of disease may have an independent impact on survival in advanced epithelial ovarian cancer (AEOC).Methods: All AEOC women were submitted to staging laparoscopy before receiving primary debulking surgery (PDS) or neoadjuvant chemotherapy (NACT). All study women received a laparoscopic score (predictive index value [PIV]) and were stratified into three groups based on volume of disease: high tumor load (HTL) for PIV ≥8, intermediate tumor load (ITL) for PIV equal to 6 and 4, and low tumor load (LTL) for PIV 1 cm in 15 cases (9.1 %). When stratifying the whole population accordi…

AdultOncologymedicine.medical_specialtyNeoplasm ResidualAdult; Aged; Aged; 80 and over; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Laparoscopy; Middle Aged; Neoplasm Staging; Neoplasm; Residual; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tumor BurdenPopulationlaparoscopySurgical oncologyInternal medicineHumansMedicineeducationLaparoscopySurvival ratePeritoneal NeoplasmsAgedNeoplasm StagingRetrospective StudiesAged 80 and overOvarian Neoplasmseducation.field_of_studymedicine.diagnostic_testPerformance statusbusiness.industryMedicine (all)Retrospective cohort studyMiddle AgedPrognosismedicine.diseaseDebulkingCombined Modality TherapyTumor BurdenSurvival Rateovarian cancerSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyFemaleSurgerybusinessOvarian cancerFollow-Up StudiesAnnals of Surgical Oncology
researchProduct